NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.17 -0.10 (-1.59 %)
(As of 05/20/2018 03:24 PM ET)
Previous Close$6.17
Today's Range$6.15 - $6.36
52-Week Range$3.61 - $12.22
Volume22,651 shs
Average Volume26,435 shs
Market Capitalization$95.23 million
P/E Ratio-6.30
Dividend YieldN/A
Beta2.72

About Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals logoGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Debt-to-Equity RatioN/A
Current Ratio5.90
Quick Ratio5.90

Price-To-Earnings

Trailing P/E Ratio-6.30
Forward P/E Ratio-8.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.09 million
Price / Sales87.40
Cash FlowN/A
Price / CashN/A
Book Value$0.88 per share
Price / Book7.01

Profitability

EPS (Most Recent Fiscal Year)($0.98)
Net Income$-12,290,000.00
Net Margins-1,073.09%
Return on Equity-110.46%
Return on Assets-83.72%

Miscellaneous

Employees16
Outstanding Shares15,440,000

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals (NASDAQ:GLMD) issued its quarterly earnings data on Wednesday, May, 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company earned $0.27 million during the quarter, compared to the consensus estimate of $0.29 million. Galmed Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 1,073.09%. View Galmed Pharmaceuticals' Earnings History.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Galmed Pharmaceuticals.

What price target have analysts set for GLMD?

4 brokers have issued 1-year target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $14.00 to $32.00. On average, they expect Galmed Pharmaceuticals' share price to reach $22.25 in the next twelve months. View Analyst Ratings for Galmed Pharmaceuticals.

What are Wall Street analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (5/15/2018)
  • 2. Maxim Group analysts commented, "Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies." (11/9/2017)

Who are some of Galmed Pharmaceuticals' key competitors?

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:
  • Mr. Allen Baharaff, Chief Exec. Officer, Pres and Director (Age 53)
  • Mr. Yohai Stenzler CPA, Chief Financial Officer and Controller (Age 35)
  • Mr. Guy Nehemya, VP of Operations (Age 33)
  • Dr. Liat Hayardeny Ph.D., MBA, Chief Scientific Officer (Age 51)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Media headlines about GLMD stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.23 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Park West Asset Management LLC (2.36%), UBS Group AG (0.26%) and A.R.T. Advisors LLC (0.12%). View Institutional Ownership Trends for Galmed Pharmaceuticals.

Which major investors are buying Galmed Pharmaceuticals stock?

GLMD stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, UBS Group AG and A.R.T. Advisors LLC. View Insider Buying and Selling for Galmed Pharmaceuticals.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $6.17.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $95.23 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 16 workers across the globe.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.


MarketBeat Community Rating for Galmed Pharmaceuticals (GLMD)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  370
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galmed Pharmaceuticals (NASDAQ:GLMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Galmed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.25, suggesting that the stock has a possible upside of 260.62%. The high price target for GLMD is $32.00 and the low price target for GLMD is $14.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.753.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.25$22.25$22.25$20.75
Price Target Upside: 260.62% upside313.57% upside135.20% upside181.17% upside

Galmed Pharmaceuticals (NASDAQ:GLMD) Consensus Price Target History

Price Target History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Maxim GroupSet Price TargetBuy$14.00LowView Rating Details
2/12/2018HC WainwrightBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.00LowView Rating Details
11/15/2017Roth CapitalInitiated CoverageBuy ➝ Buy$32.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$19.00N/AView Rating Details
8/5/2016FBR & CoSet Price TargetBuy$20.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Galmed Pharmaceuticals (NASDAQ:GLMD) Earnings History and Estimates Chart

Earnings by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.04)($0.04)($0.04)

Galmed Pharmaceuticals (NASDAQ GLMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018        
5/16/20183/31/2018($0.23)($0.17)$0.29 million$0.27 millionViewN/AView Earnings Details
3/13/2018Not Specified($0.23)($0.27)$0.28 million$0.27 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.27)($0.23)$0.26 million$0.27 millionViewN/AView Earnings Details
7/31/20176/30/2017($0.33)($0.22)$0.29 million$0.27 millionViewN/AView Earnings Details
5/15/20173/31/2017($0.39)($0.26)$0.29 million$0.27 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.30)($0.40)$0.22 million$0.27 millionViewN/AView Earnings Details
11/7/2016Q3($0.39)($0.34)$0.19 millionViewListenView Earnings Details
8/3/2016Q216($0.35)($0.39)ViewN/AView Earnings Details
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details
7/25/2014Q2 2014($0.15)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Galmed Pharmaceuticals (NASDAQ:GLMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Galmed Pharmaceuticals (NASDAQ GLMD) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 17.66%
Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ GLMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Galmed Pharmaceuticals (NASDAQ GLMD) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Galmed Pharmaceuticals (GLMD) Will Post Quarterly Sales of $290,000.00 Brokerages Anticipate Galmed Pharmaceuticals (GLMD) Will Post Quarterly Sales of $290,000.00
www.americanbankingnews.com - May 18 at 3:50 AM
Galmed Pharmaceuticals (GLMD) Expected to Announce Earnings of -$0.15 Per ShareGalmed Pharmaceuticals (GLMD) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - May 16 at 1:04 PM
Galmed Pharmaceuticals (GLMD) Upgraded by Zacks Investment Research to BuyGalmed Pharmaceuticals (GLMD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 15 at 2:09 PM
What’s Ahead For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)?What’s Ahead For Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)?
finance.yahoo.com - May 14 at 5:20 PM
Galmed Pharmaceuticals (GLMD) CEO Allen Baharaff on Q1 2018 Results - Earnings Call TranscriptGalmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 5:58 PM
What You Must Know About Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Market RisksWhat You Must Know About Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Market Risks
finance.yahoo.com - May 11 at 5:58 PM
BRIEF-Galmed Pharmaceuticals Q1 Loss Per Share $0.17BRIEF-Galmed Pharmaceuticals Q1 Loss Per Share $0.17
www.reuters.com - May 10 at 8:25 AM
Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim GroupGalmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim Group
www.americanbankingnews.com - May 9 at 6:45 PM
Galmed Pharmaceuticals (GLMD) Posts Quarterly  Earnings Results, Beats Estimates By $0.05 EPSGalmed Pharmaceuticals (GLMD) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - May 9 at 2:25 PM
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial ResultsGalmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 8:19 AM
Galmed Pharmaceuticals: 1Q Earnings SnapshotGalmed Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:19 AM
Galmed Pharmaceuticals (GLMD) Given Average Recommendation of "Buy" by BrokeragesGalmed Pharmaceuticals (GLMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 9 at 3:28 AM
Galmed Pharmaceuticals (GLMD) Upgraded to Hold by ValuEngineGalmed Pharmaceuticals (GLMD) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 3 at 5:12 PM
Has Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Improved Earnings Growth In Recent Times?Has Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Improved Earnings Growth In Recent Times?
finance.yahoo.com - May 3 at 8:17 AM
Galmed Pharmaceuticals (GLMD) Set to Announce Quarterly Earnings on WednesdayGalmed Pharmaceuticals (GLMD) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 1:56 PM
Non Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis Drug Development Pipeline Review 2018: 195 ...Non Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis Drug Development Pipeline Review 2018: 195 ...
www.prnewswire.com - May 1 at 8:26 AM
Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday ...Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday ...
www.prnewswire.com - May 1 at 8:26 AM
Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9Galmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9
finance.yahoo.com - May 1 at 8:26 AM
$290,000.00 in Sales Expected for Galmed Pharmaceuticals (GLMD) This Quarter$290,000.00 in Sales Expected for Galmed Pharmaceuticals (GLMD) This Quarter
www.americanbankingnews.com - April 30 at 1:50 AM
Galmed Pharmaceuticals (GLMD) Expected to Post Earnings of -$0.21 Per ShareGalmed Pharmaceuticals (GLMD) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 28 at 11:12 PM
What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years?What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years?
finance.yahoo.com - April 20 at 5:21 PM
Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASHGalmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASH
finance.yahoo.com - April 16 at 8:16 AM
Galmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Buy" from BrokeragesGalmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 14 at 3:31 AM
Zacks: Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $290,000.00Zacks: Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $290,000.00
www.americanbankingnews.com - April 13 at 1:00 AM
Galmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.21 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 11 at 11:16 PM
InMed Announces Appointment of Joshua Blacher as Chief Business OfficerInMed Announces Appointment of Joshua Blacher as Chief Business Officer
finance.yahoo.com - April 11 at 8:31 AM
Zacks Investment Research Downgrades Galmed Pharmaceuticals (GLMD) to HoldZacks Investment Research Downgrades Galmed Pharmaceuticals (GLMD) to Hold
www.americanbankingnews.com - April 7 at 3:22 PM
Galmed Pharmaceuticals (GLMD) Upgraded at ValuEngineGalmed Pharmaceuticals (GLMD) Upgraded at ValuEngine
www.americanbankingnews.com - April 4 at 12:02 AM
Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct OfferingGalmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering
finance.yahoo.com - April 3 at 8:24 AM
Galmed Pharmaceuticals (GLMD) Rating Lowered to Strong Sell at ValuEngineGalmed Pharmaceuticals (GLMD) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 28 at 11:55 AM
Zacks: Brokerages Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Post Quarterly Sales of $290,000.00Zacks: Brokerages Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Post Quarterly Sales of $290,000.00
www.americanbankingnews.com - March 28 at 10:53 AM
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on ...Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on ...
www.prnewswire.com - March 27 at 5:14 PM
Galmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim GroupGalmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - March 27 at 11:30 AM
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASLGalmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
finance.yahoo.com - March 27 at 8:27 AM
Galmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from BrokeragesGalmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 20 at 3:34 AM
Galmed Pharmaceuticals Ltd to Post Q1 2018 Earnings of ($0.19) Per Share, SunTrust Banks Forecasts (GLMD)Galmed Pharmaceuticals Ltd to Post Q1 2018 Earnings of ($0.19) Per Share, SunTrust Banks Forecasts (GLMD)
www.americanbankingnews.com - March 16 at 8:18 AM
Galmed Pharmaceuticals (GLMD) Upgraded to "Sell" by ValuEngineGalmed Pharmaceuticals (GLMD) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
Aramchols Failed Past Isnt Its Future; Galmed Gets An UpgradeAramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade
finance.yahoo.com - March 15 at 6:12 PM
Galmed Pharmaceuticals (GLMD) Raised to "Buy" at Maxim GroupGalmed Pharmaceuticals (GLMD) Raised to "Buy" at Maxim Group
www.americanbankingnews.com - March 15 at 8:08 AM
Galmed Pharmaceuticals (GLMD) to Release Earnings on WednesdayGalmed Pharmaceuticals (GLMD) to Release Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:16 AM
Galmed Pharmaceuticals (GLMD) Releases  Earnings Results, Misses Estimates By $0.04 EPSGalmed Pharmaceuticals (GLMD) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 13 at 10:56 AM
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateGalmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:25 AM
Galmed Pharmaceuticals (GLMD) to Release Earnings on TuesdayGalmed Pharmaceuticals (GLMD) to Release Earnings on Tuesday
www.americanbankingnews.com - March 6 at 9:19 AM
Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13
finance.yahoo.com - March 5 at 8:17 AM
Galmed Pharmaceuticals to Participate in Investor Conferences in MarchGalmed Pharmaceuticals to Participate in Investor Conferences in March
finance.yahoo.com - March 2 at 8:16 AM
Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Path To ProfitabilityGalmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Path To Profitability
finance.yahoo.com - March 1 at 8:15 AM
Galmed Pharmaceuticals (GLMD) Downgraded by ValuEngineGalmed Pharmaceuticals (GLMD) Downgraded by ValuEngine
www.americanbankingnews.com - February 28 at 10:16 PM
Galmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Hold" from AnalystsGalmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - February 22 at 3:06 PM
Galmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.23 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 20 at 1:22 AM

SEC Filings

Galmed Pharmaceuticals (NASDAQ:GLMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galmed Pharmaceuticals (NASDAQ:GLMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galmed Pharmaceuticals (NASDAQ GLMD) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.